ESTRO 37 Abstract book

S1198

ESTRO 37

4 Università "G. D’Annunzio", Department of Cardiac Surgery, Chieti, Italy Purpose or Objective Ventricular Assist Device (VAD) improves quality of life in patients with heart failure. However, it is crucial to ensure its functionality if they are exposed to radiotherapy. This work, the first one on Jarvik 2000 VAD, aims at performing measurements of basic operating parameters in vitro setting under high-energy photon beams. Material and Methods The Jarvik 2000 System consisted of a turbine pump (diameter 2.5cm, length 5.5cm, weight 85g) with a neodymium-iron-boron magnet impeller supported by ceramic bearings and housed inside a titanium-welded shell. At 8-12Krpm rotation speed, it generated a5- 7L/min flow rate. Implanted in left ventricle, the VAD made blood flow, through the anastomized effusion into the descending thoracic aorta with Hemashield 16mm discharge prosthesis and ensured the perfusion of the organs. All this was possible thanks to the alternation of the two operating states: S1 (high speed in 64sec.) and S2 (low speed in 8sec). The device was connected to an external FlowMaker controller delivering power via a tunnelled driveline from a lithium ion battery. The controller allowed manual adjustments of pump speed. All measurements were performed with the full charged battery. The in vitro setting (Fig.1) consisted of a RW3 phantom with Plexiglas siliconized box filled by deionized water where the pump was immersed and connected to FlowMaker, 1.5m away from pump. The pump was located and irradiated at the isocenter of a Synergy Agility (Elekta, Crawley) using 10MV photon beam (to minimize neutron activation), 1000 M.U. and 20x20cm 2 field. Voltage, current and frequency, parameters of VAD alternating power supply, were initially measured to establish reference values in the BaseLine session. These values were then compared to those obtained immediately before (PreRad session), during and immediately after irradiation (Irradiation and PostRad sessions, respectively). The same parameters were also measured two months later (Final verification session). After each session, the pump was left running till battery life. The whole set of measurements took six months.

protocol. Ireland’s first RTQA programme was established concurrent with the opening of the CTRIAL-IE (ICORG) 10- 14/Neo-AEGIS clinical trial, the first Irish trial involving radiotherapy to be opened internationally, in 2016. The RTQA programme was designed to provide: • Systematic quality review of the radiotherapy delivered to patients at all participating institutions A solution for the secure transfer of anonymised electronic clinical data pertaining to diagnosis and treatment a method by which the data, including RT treatment plans, can be efficiently and objectively reviewed Material and Methods The RTQA team consists of two consultant radiation oncologists, a radiotherapy medical physicist and a clinical research associate. For each trial, a CT dataset, a structure set (organ and target outlines) and sample RT plans are selected to serve as benchmarks for reference for the performance of other institutions. A secure file transfer system allows for easy and secure exchange of large data sets (including anonymised diagnostic scans, medical reports, RT plans and RT delivery reports) between the participating hospitals and the RTQA team. Finally, Sun Nuclear’s PlanIQ software package provides a platform upon which the transferred data is displayed, reviewed, and assessed for overall treatment plan quality. PlanIQ incorporates a DICOM viewer with scoring algorithms designed to extract and score treatment metrics. Members of the RTQA team meet regularly to qualitatively review and quantitatively evaluate the submitted clinical data and RT plans. Initially, participating centres are asked to complete the benchmark cases. Each submitted plan is processed in PlanIQ where all relevant dose volume metrics are compared against the trial’s expected values. Deviations from trial protocol are highlighted to the participating hospital along with mechanisms for correction This communication continues iteratively until an acceptable plan is achieved. Monitoring of plan quality continues throughout the recruitment period with evaluation of plans from randomly selected patients enrolled in the trial. Results This project has established a programme that provides the framework for the quality assurance and safe delivery of consistent RT treatment across all hospitals participating in Irish-led oncology clinical trials. Since its launch in 2016, two oncology trials have availed of this framework (CTRIAL (ICORG) 10-14/Neo-AEGIS and CTRIAL (ICORG) 12-38/Tri LARC), resulting in the assessment of patient treatments designed by 9 radiation oncologists and dosimetrists in 7 hospitals located in 4 countries. Conclusion This robust and seamless model can easily be adapted for use within any RT clinical trial in Ireland. Its development has enhanced our potential for leadership of clinical trials and ensures high quality and consistency within these trials. EP-2165 Preliminary results of Jarvik 2000 irradiation with high-energy photon beams. R. Gimenez De Lorenzo 1,2 , R. Navarra 2,3 , D. Marinelli 4 , N. Adorante 2 , S. Giancaterino 2 , D. Genovesi 2 , G. Di Giammarco 4 , M.D. Falco 2 1 Azienda Ospedaliera-Universitaria Ospedali Riuniti, Department of Radiation Oncology, Foggia, Italy 2 Università "G. D’Annunzio", Department of Radiation Oncology, Chieti, Italy 3 Università "G. D’Annunzio", Department of Neuroimaging and Cognitive Science, Chieti, Italy • •

Results No changes were recorded in the registered parameters, i.e. after each session, the VAD system worked stably.